Literature DB >> 18226970

Predictors of nonalcoholic steatohepatitis in patients undergoing bariatric surgery: when is liver biopsy indicated?

Thomas S Helling1, John H Helzberg, Jagdish S Nachnani, Krishna Gurram.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease is a frequent accompaniment of morbid obesity. A component of nonalcoholic fatty liver disease, steatosis, can, on occasion, lead to nonalcoholic steatohepatitis (NASH). Bariatric surgery has been shown to alter the course of this disease. Intraoperative liver biopsies might identify patients with NASH for more careful follow-up. We sought to determine noninvasive preoperative indicators of NASH.
METHODS: The patients scheduled for bariatric surgery underwent a preoperative assessment. The study variables included age, gender, race, body mass index, diabetes mellitus, hypertension, and the results of serum liver function tests and triglyceride, cholesterol, iron, and prealbumin measurements. Univariate and multivariate analyses were performed to identify significant variables associated with NASH as determined by subsequent core liver biopsies taken during open Roux-en-Y gastric bypass.
RESULTS: A total of 139 patients were entered into the study. NASH or NASH-associated fibrosis was found in 57 patients (41%). On univariate analyses, male gender (odds ratio [OR] 2.46, P = .06), diabetes mellitus (OR 2.60, P = .009), elevated serum triglyceride levels (OR 1.003, P = .02), elevated gamma glutamyl transferase (OR 1.015, P = .01), and decreased prealbumin (OR 0.94, P = .04) correlated with the presence of NASH. On multivariate analysis, only increased triglycerides (OR 1.004, P = .04) and decreased prealbumin (OR 0.88, P = .005) correlated with the presence of NASH.
CONCLUSION: NASH is a frequent accompaniment of morbid obesity in patients undergoing bariatric surgery. Univariate and multivariate analyses of the clinical parameters studied could not identify strong predictors of biopsy-verified NASH. Therefore, intraoperative biopsy remains instrumental in diagnosing NASH and providing information for additional follow-up.

Entities:  

Mesh:

Year:  2008        PMID: 18226970     DOI: 10.1016/j.soard.2007.11.007

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  6 in total

1.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

2.  Influence of Liver Disease on Perioperative Outcome After Bariatric Surgery in a Northern German Cohort.

Authors:  Stefan Wolter; Anna Duprée; Christina Coelius; Alexander El Gammal; Johannes Kluwe; Nina Sauer; Oliver Mann
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

3.  Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients.

Authors:  Anthony Petrick; Peter Benotti; G Craig Wood; Christopher D Still; William E Strodel; John Gabrielsen; David Rolston; Xin Chu; George Argyropoulos; Anna Ibele; Glenn S Gerhard
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

4.  Safety and Utility of Liver Biopsy During Bariatric Surgery in the New Zealand Setting.

Authors:  Hannah Collins; Grant Beban; John Windsor; Rishi Ram; David Orr; Nicholas Evennett; Benjamin Loveday
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

5.  Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine.

Authors:  Lauren N Bell; Lydia Lee; Romil Saxena; Kerry G Bemis; Mu Wang; Janice L Theodorakis; Raj Vuppalanchi; Mouhamad Alloosh; Michael Sturek; Naga Chalasani
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-02-18       Impact factor: 4.052

6.  The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory.

Authors:  Antônio Roberto Franchi Teixeira; Marta Bellodi-Privato; José Barreto Carvalheira; Victor Fernando Pilla; José Carlos Pareja; Luiz Augusto Carneiro D'Albuquerque
Journal:  Obes Surg       Date:  2009-12       Impact factor: 4.129

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.